Dividends Anonymous

Pfizer Cuts Back - But Is It Slimming Down for ImClone?

I think you'll see more than just one potential suitor for IMCL as the company has some very attractive assets that could return an equally nice ROI.

PFE doesn't have to do something if all they want to do is focus on their core competencies & best available opportunities. One could ever say that a number of Big Pharma's should be slimming down in an effort to focus their R&D inputs for greater value over the long-term